This study was designed to examine the relationship of these two new biomarkers (sestrin 2 and TRB3) associated with metabolic disorders and obesity in PCOS to shed light on further studies on etiopathogenesis and treatment modalities. This evidence concerns the gene SESN2 and Other metabolic disease.